The HER2 assessment methods for surgical specimens (GEA-s) and biopsy specimens (GEA-b) are slightly different in GEA system, which are briefly described as follows (Bartley et al. 2017): More than 10% of tumor cells in surgical specimens and ≥ 5 tumor cells in biopsy specimens showed HER2 IHC 3 + score, or HER2 IHC 2 + score was detected in ≥ 10% of tumor cells in surgical specimens and in ≥ 5 tumor cells in biopsy specimens, while FISH HER2/CEP17 ≥ 2.0. This evidence concerns the gene ERBB2 and neoplasm.